Tenaya Therapeutics (Tenaya Therapeutics) Days Sales Outstanding : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics Days Sales Outstanding?

Tenaya Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil. Tenaya Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Tenaya Therapeutics's Days Sales Outstanding or its related term are showing as below:

TNYA's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.665
* Ranked among companies with meaningful Days Sales Outstanding only.

Tenaya Therapeutics's Days Sales Outstanding stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Tenaya Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Tenaya Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics Days Sales Outstanding Chart

Tenaya Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Tenaya Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Tenaya Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Tenaya Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenaya Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's Days Sales Outstanding falls into.

Tenaya Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Tenaya Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Tenaya Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Tenaya Therapeutics (NAS:TNYA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Tenaya Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080

Website

https://www.tenayatherapeutics.com

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Executives

Timothy Hoey	officer: Chief Scientific Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson	officer: Chief Fin and Bus. Officer
Whittemore Tingley	officer: Chief Medical Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali	director, officer: Chief Executive Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel	director, 10 percent owner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava	director	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019